Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
PLoS Pathog ; 18(6): e1010228, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-35675358

RESUMEN

Influenza A virus (IAV) preferentially infects conducting airway and alveolar epithelial cells in the lung. The outcome of these infections is impacted by the host response, including the production of various cytokines, chemokines, and growth factors. Fibroblast growth factor-9 (FGF9) is required for lung development, can display antiviral activity in vitro, and is upregulated in asymptomatic patients during early IAV infection. We therefore hypothesized that FGF9 would protect the lungs from respiratory virus infection and evaluated IAV pathogenesis in mice that overexpress FGF9 in club cells in the conducting airway epithelium (FGF9-OE mice). However, we found that FGF9-OE mice were highly susceptible to IAV and Sendai virus infection compared to control mice. FGF9-OE mice displayed elevated and persistent viral loads, increased expression of cytokines and chemokines, and increased numbers of infiltrating immune cells as early as 1 day post-infection (dpi). Gene expression analysis showed an elevated type I interferon (IFN) signature in the conducting airway epithelium and analysis of IAV tropism uncovered a dramatic shift in infection from the conducting airway epithelium to the alveolar epithelium in FGF9-OE lungs. These results demonstrate that FGF9 signaling primes the conducting airway epithelium to rapidly induce a localized IFN and proinflammatory cytokine response during viral infection. Although this response protects the airway epithelial cells from IAV infection, it allows for early and enhanced infection of the alveolar epithelium, ultimately leading to increased morbidity and mortality. Our study illuminates a novel role for FGF9 in regulating respiratory virus infection and pathogenesis.


Asunto(s)
Factor 9 de Crecimiento de Fibroblastos , Virus de la Influenza A , Gripe Humana , Interferón Tipo I , Infecciones por Orthomyxoviridae , Animales , Citocinas/metabolismo , Células Epiteliales/metabolismo , Factor 9 de Crecimiento de Fibroblastos/biosíntesis , Humanos , Virus de la Influenza A/metabolismo , Gripe Humana/metabolismo , Gripe Humana/virología , Interferón Tipo I/metabolismo , Ratones , Infecciones por Orthomyxoviridae/metabolismo , Infecciones por Orthomyxoviridae/virología
2.
Immunity ; 54(11): 2547-2564.e7, 2021 11 09.
Artículo en Inglés | MEDLINE | ID: mdl-34715017

RESUMEN

Cryptosporidium can cause severe diarrhea and morbidity, but many infections are asymptomatic. Here, we studied the immune response to a commensal strain of Cryptosporidium tyzzeri (Ct-STL) serendipitously discovered when conventional type 1 dendritic cell (cDC1)-deficient mice developed cryptosporidiosis. Ct-STL was vertically transmitted without negative health effects in wild-type mice. Yet, Ct-STL provoked profound changes in the intestinal immune system, including induction of an IFN-γ-producing Th1 response. TCR sequencing coupled with in vitro and in vivo analysis of common Th1 TCRs revealed that Ct-STL elicited a dominant antigen-specific Th1 response. In contrast, deficiency in cDC1s skewed the Ct-STL CD4 T cell response toward Th17 and regulatory T cells. Although Ct-STL predominantly colonized the small intestine, colon Th1 responses were enhanced and associated with protection against Citrobacter rodentium infection and exacerbation of dextran sodium sulfate and anti-IL10R-triggered colitis. Thus, Ct-STL represents a commensal pathobiont that elicits Th1-mediated intestinal homeostasis that may reflect asymptomatic human Cryptosporidium infection.


Asunto(s)
Criptosporidiosis/inmunología , Criptosporidiosis/parasitología , Cryptosporidium/inmunología , Células Dendríticas/inmunología , Interacciones Huésped-Parásitos/inmunología , Mucosa Intestinal/inmunología , Mucosa Intestinal/parasitología , Células TH1/inmunología , Animales , Células Dendríticas/metabolismo , Modelos Animales de Enfermedad , Homeostasis , Mucosa Intestinal/metabolismo , Ratones , Microbiota , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/metabolismo , Células TH1/metabolismo
3.
Cell Rep ; 31(11): 107772, 2020 06 16.
Artículo en Inglés | MEDLINE | ID: mdl-32553163

RESUMEN

ISG15 is a ubiquitin-like modifier that also functions extracellularly, signaling through the LFA-1 integrin to promote interferon (IFN)-γ release from natural killer (NK) and T cells. The signals that lead to the production of extracellular ISG15 and the relationship between its two core functions remain unclear. We show that both epithelial cells and lymphocytes can secrete ISG15, which then signals in either an autocrine or paracrine manner to LFA-1-expressing cells. Microbial pathogens and Toll-like receptor (TLR) agonists result in both IFN-ß-dependent and -independent secretion of ISG15, and residues required for ISG15 secretion are mapped. Intracellular ISGylation inhibits secretion, and viral effector proteins, influenza B NS1, and viral de-ISGylases, including SARS-CoV-2 PLpro, have opposing effects on secretion of ISG15. These results establish extracellular ISG15 as a cytokine-like protein that bridges early innate and IFN-γ-dependent immune responses, and indicate that pathogens have evolved to differentially inhibit the intracellular and extracellular functions of ISG15.


Asunto(s)
Citocinas/metabolismo , Transducción de Señal , Ubiquitinas/metabolismo , Animales , Células HEK293 , Humanos , Gripe Humana/inmunología , Gripe Humana/metabolismo , Interferón gamma/inmunología , Interferón gamma/metabolismo , Células Jurkat , Ratones , Ratones Endogámicos C57BL , Infecciones por Mycobacterium/inmunología , Infecciones por Mycobacterium/metabolismo , Moléculas de Patrón Molecular Asociado a Patógenos , Fiebre Tifoidea/inmunología , Fiebre Tifoidea/metabolismo , Proteínas no Estructurales Virales/metabolismo
4.
PLoS Pathog ; 15(8): e1007993, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31465513

RESUMEN

Chikungunya virus (CHIKV) is an arthritogenic alphavirus that acutely causes fever as well as severe joint and muscle pain. Chronic musculoskeletal pain persists in a substantial fraction of patients for months to years after the initial infection, yet we still have a poor understanding of what promotes chronic disease. While replicating virus has not been detected in joint-associated tissues of patients with persistent arthritis nor in various animal models at convalescent time points, viral RNA is detected months after acute infection. To identify the cells that might contribute to pathogenesis during this chronic phase, we developed a recombinant CHIKV that expresses Cre recombinase (CHIKV-3'-Cre). CHIKV-3'-Cre replicated in myoblasts and fibroblasts, and it induced arthritis during the acute phase in mice. Importantly, it also induced chronic disease, including persistent viral RNA and chronic myositis and synovitis similar to wild-type virus. CHIKV-3'-Cre infection of tdTomato reporter mice resulted in a population of tdTomato+ cells that persisted for at least 112 days. Immunofluorescence and flow cytometric profiling revealed that these tdTomato+ cells predominantly were myofibers and dermal and muscle fibroblasts. Treatment with an antibody against Mxra8, a recently defined host receptor for CHIKV, reduced the number of tdTomato+ cells in the chronic phase and diminished the levels of chronic viral RNA, implicating these tdTomato+ cells as the reservoir of chronic viral RNA. Finally, isolation and flow cytometry-based sorting of the tdTomato+ fibroblasts from the skin and ankle and analysis for viral RNA revealed that the tdTomato+ cells harbor most of the persistent CHIKV RNA at chronic time points. Therefore, this CHIKV-3'-Cre and tdTomato reporter mouse system identifies the cells that survive CHIKV infection in vivo and are enriched for persistent CHIKV RNA. This model represents a useful tool for studying CHIKV pathogenesis in the acute and chronic stages of disease.


Asunto(s)
Artritis Experimental/virología , Fiebre Chikungunya/virología , Virus Chikungunya/patogenicidad , Dermis/patología , Fibroblastos/patología , Músculo Esquelético/patología , ARN Viral/metabolismo , Animales , Artritis Experimental/metabolismo , Artritis Experimental/patología , Fiebre Chikungunya/metabolismo , Virus Chikungunya/genética , Dermis/metabolismo , Dermis/virología , Modelos Animales de Enfermedad , Fibroblastos/metabolismo , Fibroblastos/virología , Ratones , Ratones Endogámicos C57BL , Fibras Musculares Esqueléticas/metabolismo , Fibras Musculares Esqueléticas/patología , Fibras Musculares Esqueléticas/virología , Músculo Esquelético/metabolismo , Músculo Esquelético/virología , ARN Viral/genética , Replicación Viral
5.
Microbes Infect ; 19(4-5): 249-258, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28087453

RESUMEN

Mycobacterium tuberculosis infection results in 1.5 million deaths annually. Type I interferon (IFN) signaling through its receptor IFNAR correlates with increased severity of disease, although how this increases susceptibility to M. tuberculosis remains uncertain. ISG15 is one of the most highly induced interferon stimulated genes (ISGs) during M. tuberculosis infection. ISG15 functions by conjugation to target proteins (ISGylation), by noncovalent association with intracellular proteins, and by release from the cell. Recent studies indicated that ISG15 can function via conjugation-independent mechanisms to suppress the type I IFN response. These data raised the question of whether ISG15 may have diverse and sometimes opposing functions during M. tuberculosis infection. To address this, we analyzed ISGylation during M. tuberculosis infection and show that ISGylated proteins accumulate following infection in an IFNAR-dependent manner. Type I IFN and ISG15 both play transient roles in promoting bacterial replication. However, as the disease progresses, ISGylation deviates from the overall effect of type I IFN and, ultimately, mice deficient in ISGylation are significantly more susceptible than IFNAR mice. Our data demonstrate that ISGs can both protect against and promote disease and are the first to report a role for ISGylation during M. tuberculosis infection.


Asunto(s)
Citocinas/genética , Interferón Tipo I/inmunología , Mycobacterium tuberculosis/inmunología , Receptor de Interferón alfa y beta/genética , Tuberculosis Pulmonar/patología , Animales , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Mycobacterium tuberculosis/metabolismo , Unión Proteica/fisiología , Transducción de Señal/genética , Transducción de Señal/inmunología , Tuberculosis Pulmonar/microbiología , Ubiquitinas/genética
6.
PLoS Pathog ; 7(10): e1002322, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22028657

RESUMEN

Chikungunya virus (CHIKV) is a re-emerging alphavirus that has caused significant disease in the Indian Ocean region since 2005. During this outbreak, in addition to fever, rash and arthritis, severe cases of CHIKV infection have been observed in infants. Challenging the notion that the innate immune response in infants is immature or defective, we demonstrate that both human infants and neonatal mice generate a robust type I interferon (IFN) response during CHIKV infection that contributes to, but is insufficient for, the complete control of infection. To characterize the mechanism by which type I IFNs control CHIKV infection, we evaluated the role of ISG15 and defined it as a central player in the host response, as neonatal mice lacking ISG15 were profoundly susceptible to CHIKV infection. Surprisingly, UbE1L⁻/⁻ mice, which lack the ISG15 E1 enzyme and therefore are unable to form ISG15 conjugates, displayed no increase in lethality following CHIKV infection, thus pointing to a non-classical role for ISG15. No differences in viral loads were observed between wild-type (WT) and ISG15⁻/⁻ mice, however, a dramatic increase in proinflammatory cytokines and chemokines was observed in ISG15⁻/⁻ mice, suggesting that the innate immune response to CHIKV contributes to their lethality. This study provides new insight into the control of CHIKV infection, and establishes a new model for how ISG15 functions as an immunomodulatory molecule in the blunting of potentially pathologic levels of innate effector molecules during the host response to viral infection.


Asunto(s)
Infecciones por Alphavirus/inmunología , Virus Chikungunya/fisiología , Citocinas/inmunología , Interferón Tipo I/inmunología , Enzimas Activadoras de Ubiquitina/inmunología , Ubiquitinas/inmunología , Infecciones por Alphavirus/diagnóstico , Infecciones por Alphavirus/metabolismo , Animales , Animales Recién Nacidos , Fiebre Chikungunya , Virus Chikungunya/patogenicidad , Citocinas/metabolismo , Modelos Animales de Enfermedad , Humanos , Interferón Tipo I/metabolismo , Ratones , Ratones Endogámicos C57BL , Unión Proteica , Recombinación Genética , Estudios Retrospectivos , Enzimas Activadoras de Ubiquitina/metabolismo , Ubiquitinas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...